Overview

Intranasal Insulin in Parkinson's Disease

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This project will investigate exploratory outcomes related to the effect of intranasal insulin on cognition, mood, apathy and motor performance of subjects with Parkinson's disease over a 3 week period.

Phase:

Phase 2

Details

Lead Sponsor:

HealthPartners Institute

Treatments:

Insulin
Insulin, Globin Zinc